{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39","upperLimit":"76","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Estimated 2-year Overall Survival (OS), as well as plots of OS, will be produced using the method of Kaplan-Meier, along with 95% confidence intervals for OS. Overall survival is defined as time from the first chemotherapy administered on trial until death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cyclophosphamide IV and vincristine sulfate IV on day 1, etoposide IV on days 1-3 or PO QD on days 2-3, and prednisone PO QD on days 1-5 (CEOP administration). Patients also receive pralatrexate IV over 3-5 minutes on days 15, 22, and 29 (P administration). Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nPatients with CR or PR, per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation.\n\nprednisone: Given PO\n\ncyclophosphamide: Given IV\n\netoposide: Given PO or IV\n\nvincristine sulfate: Given IV\n\npralatrexate: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\ncomparative genomic hybridization: Correlative studies\n\ngene expression analysis: Correlative studies\n\nnucleic acid sequencing: Correlative studies\n\nmutation analysis: Correlative studies","id":"OG000","title":"Treatment (Chemotherapy and Enzyme Inhibitor Therapy)"}],"paramType":"NUMBER","populationDescription":"All evaluable patients irrespective of the total number of cycles of therapy received were included in EFS and OS analyses.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"percentage of participants analyzed"}